<?xml version="1.0" encoding="UTF-8"?>
<p>The guanosine analog ribavirin is a broad-spectrum antiviral agent with activity against RSV and other RNA viruses such as hepatitis C and Zika viruses (
 <xref rid="ref10" ref-type="bibr">Antonini et al., 2018</xref>; 
 <xref rid="ref82" ref-type="bibr">Kim et al., 2018</xref>; 
 <xref rid="ref171" ref-type="bibr">Zhurilo et al., 2018</xref>). The beneficial effect of this drug in inhibiting RSV replication was demonstrated in several studies. Ribavirin showed antiviral activity against RSV and reduced RSV lung titers in infected cotton rats (
 <xref rid="ref19" ref-type="bibr">Bonavia et al., 2011</xref>). Similarly, significant clinical benefits have been observed in children treated with aerosolized ribavirin early in infection (
 <xref rid="ref40" ref-type="bibr">Devincenzo, 2000</xref>). However, the clinical application of ribavirin is limited because of its nonspecific anti-RSV activity, risks for potential toxicity, and relatively high cost (
 <xref rid="ref136" ref-type="bibr">Sun et al., 2013</xref>).
</p>
